Pharmaceutical News

RSS

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc., has been awarded the 2014 SCRIP Lifetime Achievement Award, one of the most prestigious of its kind in the pharmaceutical and biotechnology industries worldwide.

5 Dec 2014

Two medical imaging techniques could predict effectiveness of TB drugs

Two medical imaging techniques, called positron emission tomography (PET) and computed tomography (CT), could be used in combination as a biomarker to predict the effectiveness of antibiotic drug regimens being tested to treat tuberculosis (TB) patients, according to researchers at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

5 Dec 2014

Added benefit of nalmefene not proven for alcohol dependence

Nalmefene (trade name Selincro) has been approved since February 2013 for people with alcohol dependence who currently drink a lot of alcohol, but who do not have physical withdrawal symptoms and who do not require immediate detoxification. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in this patient group.

5 Dec 2014

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients.

4 Dec 2014

MRIGlobal awarded $3 million contract to provide HPV vaccine

MRIGlobal today announced that it has been awarded a $3 million contract amendment from the National Cancer Institute's PREVENT Cancer Program to provide a vaccine for the Human Papillomavirus or HPV, the most common sexually transmitted infection in the United States. MRIGlobal will lead a team that will produce the vaccine to be used in a Phase I clinical trial.

4 Dec 2014

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London.

4 Dec 2014

Oncologists examine efficacy of rose bengal against cancer

Rose Bengal has been around for decades starting as a way to dye wool. Originally used in medicine as a stain for ophthalmologists, it has a solid safety record going back to the 1930s. Recently, oncologists have examined its efficacy against cancer, specifically melanoma.

4 Dec 2014

New collaborative project aims to generate 3% productivity boost at Australian pharmaceutical sites

META, a collaborative network of high potential manufacturing businesses and researchers, has today announced a collaborative project between Hospira, GlaxoSmithKline and CSL to generate a targeted 3% productivity boost with an estimated return on investment of up to $2.4M dollars at Australian pharmaceutical sites.

4 Dec 2014

Endocrinologist examines benefits and harms of testosterone therapy

An article in the latest edition of Australian Prescriber looks at the prescribing of testosterone, often used for ‘male menopause’ symptoms such as reduced energy, poor concentration and increased body fat. Over the past decade there has been a steep rise in the amount of testosterone dispensed in Australia and globally.

4 Dec 2014

Non-ergot derived dopamine agonists may be safe for the heart

Non-ergot derived dopamine agonists used to treat Parkinson's disease may be safe for the heart, according to preliminary research presented at EuroEcho-Imaging 2014 by Dr Hilal Erken Pamukcu, cardiologist at Ankara Diskapi Education and Research Hospital in Turkey.

4 Dec 2014

New targeted therapy shows promise in patients with ALK-positive advanced NSCLC

An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.

4 Dec 2014

Study explores association between statin use and cataracts

Few classes of drugs have had such a transformative effect on the prevention of cardiovascular disease (CVD) as have statins, prescribed to reduce total cholesterol and low-density lipoprotein cholesterol.

4 Dec 2014

Researchers identify biochemical mechanism that could lead to 'chemo brain'

UNC School of Medicine researchers have found for the first time a biochemical mechanism that could be a cause of "chemo brain" - the neurological side effects such as memory loss, confusion, difficulty thinking, and trouble concentrating that many cancer patients experience while on chemotherapy to treat tumors in other parts of the body.

4 Dec 2014

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital.

4 Dec 2014

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, today announces that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties.

4 Dec 2014

PulmoFlow's nebulized drug and device combination gets FDA approval for cystic fibrosis

On Tuesday, the FDA granted final approval of PulmoFlow, Inc.'s New Drug Application for Kitabis Pak – a co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS Nebulizer. This is the first nebulized drug and device combination to be approved for patients with cystic fibrosis.

3 Dec 2014

Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Although some guidelines recommend use of bisphosphonates (a class of drugs used to strengthen bone) for men on androgen deprivation therapy, an analysis finds that prescriptions for these drugs remains low, even for those men at high risk of subsequent fractures, according to a study in the December 3 issue of JAMA.

3 Dec 2014

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Monash University and 60P Australia Pty Ltd, a subsidiary of 60° Pharmaceuticals LLC, have announced today an exclusive partnering deal, with 60P obtaining rights to develop the drug Fenretinide for dengue fever.

2 Dec 2014

Perrigo receives final FDA approval for diclofenac sodium topical solution 1.5% w/w

Perrigo Company plc today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for diclofenac sodium topical solution 1.5% w/w. Shipments to our pharmacy customers have commenced.

2 Dec 2014

BioPharmX submits request for pre-IND meeting to FDA for topical antibiotic acne compound

BioPharmX Corporation, a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration for the company's topical antibiotic acne compound currently under development.

2 Dec 2014

Pharmaceutical News

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Two medical imaging techniques could predict effectiveness of TB drugs

Added benefit of nalmefene not proven for alcohol dependence

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

MRIGlobal awarded $3 million contract to provide HPV vaccine

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Oncologists examine efficacy of rose bengal against cancer

New collaborative project aims to generate 3% productivity boost at Australian pharmaceutical sites

Endocrinologist examines benefits and harms of testosterone therapy

Non-ergot derived dopamine agonists may be safe for the heart

New targeted therapy shows promise in patients with ALK-positive advanced NSCLC

Study explores association between statin use and cataracts

Researchers identify biochemical mechanism that could lead to 'chemo brain'

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

PulmoFlow's nebulized drug and device combination gets FDA approval for cystic fibrosis

Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Perrigo receives final FDA approval for diclofenac sodium topical solution 1.5% w/w

BioPharmX submits request for pre-IND meeting to FDA for topical antibiotic acne compound

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News